會(huì)員.png)
5
當(dāng)前位置：廣州市艾貝泰生物科技有限公司>>公司動(dòng)態(tài)>>會(huì)議邀請(qǐng)丨艾貝泰誠邀您參加2024全球生物醫(yī)藥制藥工程論壇暨ISPE中國年會(huì)
會(huì)議邀請(qǐng)丨艾貝泰誠邀您參加2024全球生物醫(yī)藥制藥工程論壇暨ISPE中國年會(huì)
9個(gè)論壇
66個(gè)學(xué)術(shù)主題，13位國際講者
現(xiàn)場近500余人參會(huì)，線上超萬人觀看
會(huì)議時(shí)間、地點(diǎn)
2024年4月12~13日
（周五~周六）
中國·杭州
浙商開元名都酒店
艾貝泰展位號(hào)：B10
會(huì)議日程
主論壇
Main Forum
★
4月12日 12th Apr.（周五Fri.）
08：30-12：00
主持人暖場致辭
Warmup Speech
大會(huì)開幕啟動(dòng)儀式
Opening Ceremony
FDA中國辦公室官員演講
FDA China Official Speech
FDA‘s view point on advanced pharmaceuticals manufacturing
貝妮娜 Tonia Bernard
公共衛(wèi)生碩士
助理主任，F(xiàn)DA中國辦公室
MPH
Assistant Country Director, FDA China Office
FOYA 2023獲獎(jiǎng)介紹
FOYA 2023 Introduction
八大論壇，聚焦制藥工程全鏈路
包括生物制藥、基因與細(xì)胞治療（GCT）、化學(xué)制藥、工程設(shè)計(jì)和項(xiàng)目管理、生產(chǎn)工程、合規(guī)、制藥供應(yīng)鏈、創(chuàng)新投資八大論壇版塊，涉及到行業(yè)內(nèi)各個(gè)領(lǐng)域的最新動(dòng)態(tài)。
生物制藥分論壇
Biological Drug Forum
李錦才 Jimmy LI
藥明合聯(lián) CEO
CEO，WuXi XDC
聚焦生物制藥行業(yè)高度關(guān)注話題，結(jié)合指南，分享企業(yè)實(shí)操經(jīng)驗(yàn)
Focusing on the hot topics of the Biologics industry, sharing relevant guidance documents and good practices from pharmaceutical companies.
4月12日 12th Apr.（周五Fri.）
13：00-16：30
隔離器無菌生產(chǎn)的挑戰(zhàn)
Challenges with Aseptic Production in An Isolator
顧晨 Chen GU
技術(shù)總監(jiān)，星德科包裝技術(shù)（杭州）有限公司
Technical director，Syntegon
指南介紹：活性化合物的遏制
Introduction for Good Practice Guide： Containment for Potent Compound
Dr. Rainer Nicolai
Product Owner Engineering Consulting
F. Hoffmann - La Roche AG
高活化合物的處理和操作
Handling and Operation of potent compounds
朱人 William Ren ZHU
Golder IH業(yè)務(wù)負(fù)責(zé)人，科進(jìn)公司
Associate Director, Environment, WSP
企業(yè)對(duì)高活化合物的綜合管理
Management of highly potent compounds by pharmaceutical companies
羅建軍博士 Dr. J.J LUO
生物偶聯(lián)產(chǎn)品研發(fā)和生產(chǎn)副總裁
藥明合聯(lián)
Vice President of Bioconjugate Product Development and Manufacturing WuXi XDC
4月13日 13th Apr.（周六 Sat.）
09：00-12：00
指南介紹：APQ：PPPQMS
Introduction for APQ Guide：Process Performance & Product Quality Monitoring System (PPPQMS)
Mr. Maurice B. Parlane B Tech MIT
Principal
New Wayz Consulting Ltd
持續(xù)工藝監(jiān)控和改進(jìn)
Continued process monitoring and improvement
溫源博士 Dr. Yuan WEN
全球生產(chǎn)部MFG1和MFG4的負(fù)責(zé)人，藥明生物
head of MFG1 and MFG4 of Global Manufacturing，WuXi Biologics
自我注射系統(tǒng)及新材料預(yù)灌封系統(tǒng)在注射劑上的應(yīng)用
Application of self-injection system and polymer materials in injections
郭融 William GUO
研發(fā)副總裁
上海新耀湃科醫(yī)療科技股份有限公司
Vice President R&D for Shanghai Innopac
國產(chǎn)生物創(chuàng)新藥出海美國策略分享
王剛 Gang WANG
執(zhí)行董事、高級(jí)副總裁兼質(zhì)量官
上海君實(shí)生物工程有限公司
Executive Director, Senior Vice President and Chief Quality Officer
Shanghai Junshi Biotechnology Co., Ltd
新型一次性碟片式離心機(jī)在收獲工藝環(huán)節(jié)的應(yīng)用
Maximizing Efficiency and Cost-saving：Thermo Fisher Single-use Centrifuge for harvest process
張龍浩 Longhao ZHANG
生物工藝部技術(shù)支持經(jīng)理，賽默飛世爾科技
Technical Support Manager, Bioprocess Department，Thermofisher
國內(nèi)企業(yè)接受EMA PAI檢查的經(jīng)驗(yàn)分享
Experience sharing of China-based pharma company preparing for EMA Pre-Approval Inspection (PAI)
黃瑋 Wei HUANG
總裁，上海復(fù)宏漢霖生物制藥有限公司
President
Shanghai Henlius Biopharmaceutical Co.,Ltd.
生產(chǎn)工程分論壇
Manufacturing Engineering Forum
甘益民 Yimin GAN
上海復(fù)旦張江生物醫(yī)藥股份有限公司副總經(jīng)理
Vice General Manager，Shanghai Fudan Zhangjiang bio-pharmaceutical Co.,Ltd.
聚焦最新指南有關(guān)清潔驗(yàn)證和無菌生產(chǎn)設(shè)施，為制藥業(yè)答疑解惑
Focus on latest guidance about cleaning validation and sterile manufactiring facilities, aims to offer an instructive solution for Pharma Manufacturer.
4月13日 13th Apr.（周六 Sat.）
09：00-12：10
最新清潔驗(yàn)證指南解讀
Guide introduction: Cleaning Validation Lifecycle - Applications, Methods, & Controls
Ms. Catherine T. Oakes
Managing Director
Oakes Group Global Ltd.
標(biāo)準(zhǔn)化和自動(dòng)化對(duì)于提高產(chǎn)品合規(guī)性與生產(chǎn)效率的作用與意義
How standardization and automation improve compliance and productivity
Martin W. Goebel
Sales Director Analytics
Knick GmbH, Germany
馬強(qiáng) QIANG MA
Sales Manager - Analytics
Knick (Shanghai) Electronic Measurement Trading Co., Ltd
清潔驗(yàn)證中最差條件選擇與評(píng)估
Worst case assessment in cleaning validation
牛萍 Ping NIU
質(zhì)量與合規(guī)高級(jí)顧問，齊魯制藥
Sr. Consultant of Quality and Compliance，Qilu Pharmaceutical
生物制藥清潔驗(yàn)證經(jīng)驗(yàn)分享
Biotechnology cleaning validation good practice sharing
Richard Chai
Senior Technical Service Manager
STERIS Corporation
清潔驗(yàn)證在中藥生產(chǎn)中的實(shí)施
Cleaning validation in Chinese medicine manufacturing
孫英強(qiáng) Yingqiang SUN
質(zhì)量經(jīng)理，步長藥業(yè)
Quality Manager，Buchang Pharmaceutical
13：30-17：30
Operational Readiness
Mr John Vaughn
Vice President, Asia，CAI
新版歐盟GMP無菌附錄的主要變化及無菌保障能力提升策略
Major Changes in EU GMP Annex 1 Manufacture of Sterile Medicinal Products and Strategies for Enhancing Sterile Assurance Capabilities
張新 Xin ZHANG
顧問教授，沈陽藥科大學(xué)
Consultant professor
Shenyang Pharmaceutical University
無菌藥品生產(chǎn)設(shè)施指南解讀
Baseline Guide Vol Vol 3 introduction: Sterile Product Manufacturing Facilities 3rd Edition
Mr.Aaron Weinstein
Senior Director，Compliance Consulting
IPS-Integrated Project Services，LLC
歐美法規(guī)中關(guān)于清潔消毒的若干要點(diǎn)解讀
Lessons learnt on cleaning & disinfection regulatory observations
劉寅 Yin LIU
生命科學(xué)中國區(qū)技術(shù)支持，STERIS
隔離器的滅菌與驗(yàn)證
Sterilization and validation for Isolator
柯桂盛 Guisheng KE
海普瑞
Shenzhen Hepalink Pharmacetical GroupCo.,LTD
問與答
Q&A
合規(guī)分論壇
Regulation & Compliance Forum
孫京林 Jinglin SUN
中國生物技術(shù)股份有限公司副總裁
VP，China National Biotec Group(CNBG)
聚焦最新制藥行業(yè)形勢變化，關(guān)注生物制品MAH制度、質(zhì)量風(fēng)險(xiǎn)管理等熱點(diǎn)問題
Focus on the latest change of pharmaceutical industry, pay attention to hot topics such as the implementation of the MAH system for biological products and the quality risk management.
4月12日 12th Apr.（周五 Fri.）
13：00-17：40
生物制品MAH制度
implementation of the MAH system for biological products
潘海龍 Hailong PAN
質(zhì)量管理部主任，中國生物技術(shù)股份有限公司
Director, Quliaty Managemetn Dept. CNBG
淺析無菌操作的發(fā)展趨勢
operation trend in aseptic production
婁再飛 Zaifei LOU
驗(yàn)證與合規(guī)部門負(fù)責(zé)人
星德科包裝技術(shù)（杭州）有限公司
與國際接軌-中國版《無菌藥品生產(chǎn)污染控制策略(CCS)技術(shù)指南》介紹
肖志堅(jiān) Zhijian XIAO
中國質(zhì)量負(fù)責(zé)人，百濟(jì)神州
主任，中國醫(yī)藥設(shè)備工程協(xié)會(huì)無菌藥品先進(jìn)制造專業(yè)委員會(huì)
Head of Quality in China, Beigene
Director, Professional Commitee on Advanced Manufacturing of aseptic drugs, CPAPE
國際典型無菌檢查缺陷分析及對(duì)中國企業(yè)的啟示
Typical observations analysis in international aseptic inspections and the enlightenment for Chinese enterprises
韓亮 博士 Dr. Liang HAN
研究顧問，北京大學(xué)知識(shí)工程與監(jiān)管科學(xué)實(shí)驗(yàn)室，識(shí)林知識(shí)平臺(tái)負(fù)責(zé)人
Research Consultant, Knowledge Engineering and Regulatory Science Laboratories, BeijingUniversityHead of Shlinx
Panel
孫京林、潘海龍、婁再飛、肖志堅(jiān)、韓亮、MHRA專家
Jinglin SUN, Hailong PAN,Zaifei LOU, Zhijian XIAO, Liang HAN,MHRA SME
工程設(shè)計(jì)和項(xiàng)目管理分論壇
Engineering Design and Project Mgt Forum
康 偉 Wei KANG
香港奧星集團(tuán)副總裁
VP，Austar Group
聚焦于生物制藥設(shè)施GMP合規(guī)設(shè)計(jì)與項(xiàng)目管理，依托良好實(shí)踐指南：良好工程實(shí)踐（2021）的指導(dǎo)，深度解析并分享企業(yè)在這方面的實(shí)戰(zhàn)經(jīng)驗(yàn)
Focusing on GMP compliance design and project management of biopharmaceutical facilities, we will delve into the interpretation of Good Practice Guide： Good Engineering Practice (2021) and share practical experiences from industry operations.
4月12日 12th Apr.（周五 Fri.）
13：00-16：15
GEP指南介紹
GEP Guideline Introduction
Chip Bennett
良好實(shí)踐指南：良好工程實(shí)踐，第二版(2021年) 主要作者
Associate Director, Global C&Q | CAI
Lead Author on the Good Practice Guide: Good Engineering Practice, 2nd Edition (2021)
歐盟標(biāo)準(zhǔn)的無菌制劑廠房的污染控制策略
——基于歐盟新版附錄1案例分享
Eu standard contamination control strategy for aseptic filling plant -- Case sharing based on the new EU Appendix 1
企業(yè)解決方案高質(zhì)量、低風(fēng)險(xiǎn)，快速靈活的賦能您的生物制藥產(chǎn)能建設(shè)
Enterprise Solutions enabling your biomanufacturing capacity with high quality, low risk and high speed and flexibility
何永江 Yongjiang HE
企業(yè)解決方案高級(jí)項(xiàng)目經(jīng)理，Cytiva
Senior Project Manager, Enterprise Solutions, Cytiva
生物制藥廠房設(shè)計(jì)與實(shí)施：策略優(yōu)化與案例分析
Design and Implementation of Biopharmaceutical Manufacturing Facilities: Strategy Optimization and Case Study
Mark Stephens
Global Subject Matter Expert，Exyte
血液制品生物工廠項(xiàng)目建設(shè)管理要點(diǎn)
Key points in the construction and management of plasma manufacturing projects
郭維強(qiáng) Weiqiang GUO
上海血制副總經(jīng)理，天壇生物
Vice General Manager, Tiantan Bio
化學(xué)制藥分論壇
Chemistry Drug Forum
王衛(wèi)兵 Alex WANG
江蘇恩華藥業(yè)股份有限公司副總裁
VP，Jiangsu Nhwa Group
2023年3月6日，國家藥監(jiān)局核查中心（CFDI）組織研究起草的《藥品共線生產(chǎn)質(zhì)量管理指南》正式稿發(fā)布。國際上，ICH Q9 R1《質(zhì)量風(fēng)險(xiǎn)管理》修訂版定稿的發(fā)布，結(jié)合歐盟早已頒布的EU GMP附錄1《無菌產(chǎn)品生產(chǎn)》，制藥行業(yè)對(duì)于生產(chǎn)的各個(gè)環(huán)節(jié)以及產(chǎn)品整個(gè)生命周期里的風(fēng)險(xiǎn)管控越來越重視，尤其是污染和交叉污染的防控。國際制藥工程協(xié)會(huì)針對(duì)藥品生產(chǎn)風(fēng)險(xiǎn)管理，高活性產(chǎn)品共線生產(chǎn)等各個(gè)方面也有專門的指南，歡迎行業(yè)同仁一起來分享探討，合作共通
In March 6th, 2023, CFDI from NMPA published the official version of a guidance on Drug Manufacture with Shared Facilities. World widely, ICH Q9 “Risk Management" R1 and EU GMP Annex 1 remain hot topics of the industry, which is embraced cross the product lifecycle, especially risk of contamination & cross contamination once again becomes critical for pharmaceutical operations. Along with it, established series guidelines on those topics and we are going to discuss it during the conference. Your participation and sharing are welcome.
4月12日 12th Apr.（周五 Fri.）
13：00-17：20
基于CCS的環(huán)境監(jiān)控解決方案
CCS-based Environmental Monitoring Solution
徐敏鳳 Minfeng XU
產(chǎn)品總監(jiān)，麥克微爾（上海）科技有限公司
Chief Product Officer，Micron view
CCS ：污 染 控 制 策 略／附 件 1
CCS: Contamination Control Strategy/Annex 1
徐禾豐 Hefeng XU
行業(yè)專業(yè)人士 Industry professional
新版歐盟附錄1的主要變化及濕熱滅菌方面的實(shí)踐解讀
key highlight of revised Annex l of EU GMP and example sharing in moist heat sterilization
胡仲新 Jessica Hu
資深質(zhì)量總監(jiān)，百特上海醫(yī)療儀器有限公司
Sr. Director, Quality ，Baxter Healthcare
指南：基于風(fēng)險(xiǎn)的藥品生產(chǎn)第2版
Guidance: Risk-Based Manufacture of Pharma Products 2nd Editio
Stephanie A. Wilkins，PE
PharmaConsult US, Inc
基于風(fēng)險(xiǎn)的生產(chǎn)——理論與實(shí)踐
Risk-based production - Theory and practice
張新 Xin ZHANG
顧問教授，沈陽藥科大學(xué)
Consultant professor
Shenyang Pharmaceutical University
4月13日 13th Apr.（周六 Sat.）
13：30-17：30
運(yùn)營管理應(yīng)用分享
API: Good Practice Guide: Operations Management (guideline), intergrate with ICH Q11
周臻弘 Zhenhong ZHOU
質(zhì)量副總裁，浙江海正藥業(yè)
VP Quality，Zhejiang Hisun Pharmaceutical Co., Ltd
良好規(guī)范指南：有效化合物的防護(hù)+共用設(shè)施
Good Practice Guide：Containment for Potent Compounds+ Shared facilities
夏祿華 Luhua XIA
副總經(jīng)理，江蘇金迪克生物科技有限公司
生命周期管理：APQ指南：過程性能和產(chǎn)品質(zhì)量監(jiān)控系統(tǒng)(PPPQMS) (指南)
Lifecycle Management : APQ Guide: Process Performance & Product Quality Monitori ng System (PPPQMS) (guideline)
Mr. Maurice B. Parlane, B Tech MIT
Principal
New Wayz Consulting Ltd
PPPQMS及其在固體制劑的應(yīng)用
PPPQMS and its application in solid preparations
陳四向 Sixiang CHEN
廣東東陽光藥業(yè)股份有限公司 專家
Guangdong Sunshine Lake Pharm Co.,Ltd Expert
基因與細(xì)胞治療（GCT）分論壇
GCT Forum
高 楊 Frank GAO
行業(yè)專家
基于經(jīng)典制藥實(shí)踐，賦能新興療法發(fā)展
Leverage classic pharmaceutical best practice to empower the development of advanced theraputic medical products.
4月13日 13th Apr.（周六 Sat.）
09：00-12：10
“先進(jìn)治療產(chǎn)品-自體細(xì)胞治療指南"指導(dǎo)原則講解
Introduction for Guide：ATMPs - Autologous Cell Therapy
Jeff Odum
Practice Leader：ATMPs & Biologics
Genesis AEC
CGT設(shè)施如何設(shè)計(jì)和進(jìn)行風(fēng)險(xiǎn)控制-基于指南&GMP規(guī)范
How to design GMP facilities and conduct risk control - based on guidelines &GMP specifications
付長亮 Changliang FU
SME，奧星集團(tuán)
從毒菌污染看微生物控制策略
Looking at microbial control strategies from the perspective of moldcontamination
王曉明 Xiaoming WANG
顧問，瓦格納生物科技咨詢
制藥企業(yè)的供應(yīng)鏈體系
A world-class supply chain for pharmaceutical companies
叢征宇 Zhengyu CONG
高級(jí)副總裁，馴鹿生物
13：00-16：50
CGT產(chǎn)品GMP審計(jì)中發(fā)現(xiàn)的問題與分析
Analysis of defects found in GMP audits of CGT products
董立瑋 Liwei DONG
亞太區(qū)合規(guī)顧問，精鼎醫(yī)藥
Principal Consultant APAC Compliance,Parexel International
細(xì)胞治療/溶瘤病毒/AAV產(chǎn)品藥學(xué)變更的CMC考慮
CMC considerations for pharmaceutical changes in cell therapy/oncolytic virus /AAV products
曹曉平Ph.D. Xiaoping CAO Ph.D
CTO，藥明巨諾
CTO，JW THERAPEUTICS
對(duì)FDA關(guān)于細(xì)胞基因治療產(chǎn)品Potency方法建立指南的考慮
Consideration of FDA guidelines for the establishment of bioassay methods for CGT
劉雅容Ph.D Yarong LIU Ph.D
CEO，沙礫生物
CEO，GRIT Biotechnology
細(xì)胞治療上市前工藝驗(yàn)證
Cell therapy pre-NDA process validation
王永增 James WANG
CTO, 合源生物
CTO, JUVENTAS Bio
針對(duì)細(xì)胞和基因治療的脫靶和隨機(jī)插入的分析
Analysis of off-target and random insertions for cell and gene therapy
譚炳合，Ph.D,
生產(chǎn)與CMC副總裁，邦耀生物
Vice President, BRL Medicine
制藥供應(yīng)鏈論壇
Pharmaceutical Supply Chain Forum
王 麟 Lynn WANG
Executive Director, Global Project Management, Wuxi XDC
聚焦醫(yī)藥工程供應(yīng)鏈的挑戰(zhàn)和熱點(diǎn)，結(jié)合生產(chǎn)供應(yīng)鏈，臨床供應(yīng)鏈和供應(yīng)鏈數(shù)字化方面的更新和指南，探討中國出發(fā)的全球醫(yī)藥工程供應(yīng)鏈最佳實(shí)踐
Focusing on the challenges and hot topic of the pharmaceutical engineering supply chain, to explore the best practices of the global pharmaceutical engineering supply chain from China to global on manufacturing, clinical supply chain and supply chain digitization, with the market updates sharing and guidelines discussion.
4月13日 13th Apr.（周六 Sat.）
09：00-12：10
數(shù)字系統(tǒng)_臨床供應(yīng)鏈的期望和價(jià)值主張
Digital Systems_Expectations and Value Proposition for Clinical Supply Chain
Glasser, Barrett MBA, MPH
Senior Director, Global Clinical Supply Chain，Team Leader of Digital Clinical Supply Chain and Process Excellence
Takeda
美國食品藥品監(jiān)督管理局的檢查計(jì)劃:基于風(fēng)險(xiǎn)的設(shè)施評(píng)估方法
US FDA's Inspection Program: A Risk Based Approach to Facility Assessments
Dr. Zhihao Peter Qiu
External Advocacy Lead APAC
Roche Genentech
ICH Q5A 法規(guī)更新后對(duì)生物安全檢測的未來展望
Implementation of lCH Q5A: Expectations and Recommendations for Biosafety Testing for Biosafety of Medicinal Products
吳云飛 Dr. Yunfei Wu
技術(shù)與法規(guī)經(jīng)理，Merck
Technical and regulatory Manager，Merck
AI賦能醫(yī)藥智造的最新實(shí)踐
The latest practices of Al in smart manufacturing
陶靜雯 Tracy TAO
量子創(chuàng)新場主任
明度智云
Director of AI innovation department
Mingdu Zhiyun Technology Co.,Ltd
13：00-16：25
利用供應(yīng)商質(zhì)量管理系統(tǒng)和全球化布局保障藥品的生產(chǎn)安全
Utilizing a supplier quality management system and a globalized layout to ensure the production safety of pharmaceutical products
林森 Nathan Lin
上游工藝解決方案技術(shù)總監(jiān)，默克
多國家多中心臨床試驗(yàn)中的質(zhì)量管理策略
Quality Management Strategy in Multiple Regions Clinical Trials (MRCT)
施維維 Vela Shi
臨床試驗(yàn)事業(yè)部中國質(zhì)量負(fù)責(zé)人
賽默飛
Head of Quality, Thermo Fisher Clinical Trail Division China
臨床試驗(yàn)供應(yīng)鏈的仿真及關(guān)鍵決策優(yōu)化
Clinical Supplies Simulation and Strategic Decision Optimization
付迪宇 Diyu FU
創(chuàng)始人，戰(zhàn)略及業(yè)務(wù)發(fā)展負(fù)責(zé)人，華升智藥科技開發(fā)（北京）有限公司
茅亞超 Yachao MAO
聯(lián)合創(chuàng)始人，產(chǎn)品研發(fā)負(fù)責(zé)人，華升智藥科技開發(fā)（北京）有限公司
臨床供應(yīng)質(zhì)量管理策略
Quality Management Strategy for Clinical Supply
高曉偉 Daniel Gao
副總裁，廣州漢騰生物科技有限公司
CGT的全球臨床供應(yīng)實(shí)踐
Global Clinical Supply Practices for CGT
韋慶坤 Qingkun WEI
高騰生物
創(chuàng)新與投資分論壇
定向邀請(qǐng)（Invitation Reqired）
Innovation Investment Forum
龐飛飛 Sophie PANG
董秘，北京鼎持
Board Secretary，Beijing Dingchi Co.
本論壇旨在充分利用平臺(tái)資源優(yōu)勢，建立機(jī)制、凝聚共識(shí)、形成合力，圍繞專業(yè)+產(chǎn)業(yè)鏈構(gòu)建協(xié)作支撐的資金鏈，攜手共營良好創(chuàng)投氛圍，共搭投融資合作平臺(tái)，共促協(xié)同創(chuàng)新、成果轉(zhuǎn)化和產(chǎn)業(yè)協(xié)作
This forum aims to make full use of the resource advantages of platform, establish mechanisms, build consensus, form synergy, build a collaborative supporting capital chain around the professional + industrial chain, work together to build a good venture capital atmosphere, build investment and financing cooperation platforms, and promote collaborative innovation, achievement transformation and industrial collaboration.
4月12日 12th Apr.（周五 Fri.）
17：30 - 19：10
投行角度分享
Care Sharing on Investment Bank Perspecitve
吳虹生 Hongsheng WU
執(zhí)行董事，招商證券投資銀行委員會(huì)
Executive director, China Merchants Securities and Investment Banking Commission
國有資本視角
融資成功案例
Best Case sharing of Successful Financing
龐飛飛 Sophie PANG
董秘，北京鼎持
Board Secretary，Beijing Dingchi Co.
中國醫(yī)藥企業(yè)赴美投資動(dòng)因觀察
Observation on the motivation of Chinese pharmaceutical enterprises to invest in the United States
胡曉蕾 Rosemary Hu
合伙人，稅務(wù)及商務(wù)咨詢，企業(yè)并購重組稅務(wù)服務(wù)，德勤中國
Partner，Tax& Business Advisory ServicesMergers & Acquisitions
Deloitte China
馬里蘭州助力中國藥企出海美國市場
Maryland Offers Support to Chinese Biopharmaceuticals in Entering US Market
王艷波 Vikki WANG
馬里蘭州商務(wù)廳
Maryland Department of Commerce
艾貝泰生物科技有限公司（Applitech Biological Technology Co., Ltd.）作為一家集設(shè)計(jì)、研發(fā)、生產(chǎn)、銷售和服務(wù)于一體的高新技術(shù)企業(yè)，致力于為生物制藥領(lǐng)域提供專業(yè)的生產(chǎn)及分析設(shè)備、一次性耗材和整體解決方案。從成立至今，我們始終以客戶為中心，將“質(zhì)量為本，服務(wù)為先"作為經(jīng)營方針，立足于生物工藝的優(yōu)化、放大和生產(chǎn)，不斷完善生物制藥領(lǐng)域的產(chǎn)品線，為用戶提供生物工藝的專業(yè)解決方案，助力用戶在生物制藥領(lǐng)域不斷取得新的突破。